Quantcast

PHX Reporter

Monday, November 4, 2024

FDA issued 24 citations in cities across Maricopa County in Q4 2023

Webp h4aqt9opyxgsl1u4m9lhyfaf2aa8

Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website

Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website

There were six companies in cities associated with Maricopa County that received FDA citations as a result of six inspections conducted in the county over the fourth quarter of 2023, according to reports from the U.S. Food and Drug Administration (FDA).

This is a 20% increase over the number of companies cited in the previous quarter.

The citations in the county include:

  • The labels of the medical device(s) do not bear a unique device identifier (UDI) that meet the requirements of 801 Subpart B and 21 CFR 830.
  • Management with executive responsibility has not reviewed the suitability and effectiveness of the quality system.
  • Quality audits have not been performed.

All of the companies cited were involved in either Devices or Drugs sectors.

Of the companies cited, two should take voluntary actions to correct their managing operations (33.3%). Additionally, two companies had to take regulatory and/or administrative actions (33.3%).

The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.

The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.

Companies located within Maricopa County Cities and the citations they received in Q4 2023
Company NameArea of BusinessInspection DateIssue Cited
Abraxis Bioscience, LLCDrugs10/06/2023Procedures not in writing, fully followed
Abraxis Bioscience, LLCDrugs10/06/2023Equipment to control conditions
Abraxis Bioscience, LLCDrugs10/06/2023input/output verification
Abraxis Bioscience, LLCDrugs10/06/2023Annual visual exams of drug products
Abraxis Bioscience, LLCDrugs10/06/2023Written record of investigation incomplete
Abraxis Bioscience, LLCDrugs10/06/2023Second person sign off
AnuMed International, LLCDrugs11/07/2023Procedures not in writing, fully followed
AnuMed International, LLCDrugs11/07/2023Sanitation--buildings not clean, free of infestation
AnuMed International, LLCDrugs11/07/2023Absence of Written Procedures
AnuMed International, LLCDrugs11/07/2023Scientifically sound laboratory controls
AnuMed International, LLCDrugs11/07/2023Adequate number of batches on stability
AnuMed International, LLCDrugs11/07/2023Prepared for each batch, include complete information
Neuromechanical Innovations, LLCDevices12/13/2023Label to bear a unique device identifier
Neuromechanical Innovations, LLCDevices12/13/2023Management review - defined interval, sufficient frequency
Neuromechanical Innovations, LLCDevices12/13/2023Quality Audit/Reaudit - conducted
Noraxon USA, Inc.Devices11/30/2023Calibration procedures - content
Signature Formulations, LLCDrugs11/22/2023Lack of quality control unit
Signature Formulations, LLCDrugs11/22/2023Absence of Written Procedures
Signature Formulations, LLCDrugs11/22/2023Lab controls established, including changes
Signature Formulations, LLCDrugs11/22/2023Testing and release for distribution
Signature Formulations, LLCDrugs11/22/2023Written program not followed
Signature Formulations, LLCDrugs11/22/2023Procedures to be written and followed
TAMA Research CorporationDevices10/05/2023Records of complaint investigation
TAMA Research CorporationDevices10/05/2023Devices subject to device identification GUDID data submission requirements.

MORE NEWS